This protocol describes a survey undertaken to acquire a snapshot of the distribution of Clostridioides difficile strains in tertiary acute care hospitals in the European Union/European Economic Area (EU/EEA) in 2022–2023
This joint guidance by the ECDC and EMCDDA aims to strengthen the evidence base for developing national strategies for preventing and controlling infections and infectious diseases among people who inject drugs.
Meningococcal disease is caused by Neisseria meningitidis, a bacterium with human carriers as the only reservoir. It is carried in the nose, where it can remain for long periods without producing symptoms.
This document is an update of the joint guidance that was published in 2011 by the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
Viral hepatitis is an inflammation of the liver caused by a virus. The most common hepatitis viruses in Europe are types A, B, and C (commonly referred to as HAV, HBV and HCV).
Version 6.1 is the final protocol for the third EU-wide point prevalence survey in acute care hospitals (PPS 2022–2023). It contains important changes compared to protocol version 5.3 (PPS 2016–2017), including on healthcare-associated COVID-19.
This document provides an overview of key considerations for the provision of the HIV continuum of care in the context of displaced people from Ukraine in the EU/EEA.
This reporting protocol is intended for reporting national case-based data for surveillance of hepatitis of unknown origin from all the countries and areas of the WHO European Region, including the 27 countries of the European Union (EU) and the additional three countries of the European Economic Area (EEA), to the European level.
This document provides guidance on diagnostic testing, molecular characterisation and metagenomic analysis for suspect cases of severe acute hepatitis of unknown aetiology.